- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07680764
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
-
Buenos Aires, Argentina, C1426ANZ
- Recruiting
- Instituto Medico Especializado Alexander Fleming
-
Contact:
- Claudio Martin, Site 0094
- Phone Number: 5491166936669
-
Viedma, Argentina, R8500ACE
- Recruiting
- Clinica Viedma S.A.
-
Contact:
- Ruben Kowalyszyn, Site 0092
- Phone Number: 5492920601693
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Recruiting
- Sanatorio Parque Rosario
-
Contact:
- Gaston Martinengo, Site 0082
- Phone Number: 5493416955611
-
-
-
-
New South Wales
-
Gosford, New South Wales, Australia, 2250
- Recruiting
- Gosford Hospital
-
Contact:
- Matthew Chan, Site 0074
-
Westmead, New South Wales, Australia, 2145
- Not yet recruiting
- Local Institution - 0134
-
Contact:
- Site 0134
-
-
Queensland
-
Greenslopes, Queensland, Australia, 4120
- Not yet recruiting
- Local Institution - 0167
-
Contact:
- Site 0167
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Not yet recruiting
- Local Institution - 0100
-
Contact:
- Site 0100
-
-
Western Australia
-
Perth, Western Australia, Australia, 6150
- Recruiting
- St. John of God Murdoch Hospital
-
Contact:
- Kynan Feeney, Site 0048
- Phone Number: +61894389599
-
-
-
-
-
São Paulo, Brazil, 01246-000
- Not yet recruiting
- Local Institution - 0001
-
Contact:
- Site 0001
-
-
Rio Grande do Norte
-
Natal/RN, Rio Grande do Norte, Brazil, 59062-000
- Not yet recruiting
- Local Institution - 0003
-
Contact:
- Site 0003
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 91610-000
- Not yet recruiting
- Local Institution - 0006
-
Contact:
- Site 0006
-
-
São Paulo
-
Barretos, São Paulo, Brazil, 14784
- Not yet recruiting
- Local Institution - 0005
-
Contact:
- Site 0005
-
-
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 8420383
- Recruiting
- Bradfordhill
-
Contact:
- Carlos Rojas, Site 0149
- Phone Number: +56998744662
-
Santiago, Santiago Metropolitan, Chile, 7500713
- Recruiting
- Orlandi Oncologia
-
Contact:
- Francisco Orlandi, Site 0081
- Phone Number: 56992214787
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Recruiting
- Oncocentro Apys
-
Contact:
- Alejandro Acevedo Gaete, Site 0084
- Phone Number: +56992369820
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100142
- Not yet recruiting
- Local Institution - 0038
-
Contact:
- Site 0038
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Not yet recruiting
- Local Institution - 0138
-
Contact:
- Site 0138
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Not yet recruiting
- Local Institution - 0050
-
Contact:
- Site 0050
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Not yet recruiting
- Local Institution - 0147
-
Contact:
- Site 0147
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200030
- Not yet recruiting
- Local Institution - 0140
-
Contact:
- Site 0140
-
Shanghai, Shanghai Municipality, China, 200032
- Not yet recruiting
- Local Institution - 0169
-
Contact:
- Site 0169
-
-
Sichuan
-
Chengdu, Sichuan, China, 610213
- Not yet recruiting
- Local Institution - 0144
-
Contact:
- Site 0144
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Not yet recruiting
- Local Institution - 0137
-
Contact:
- Site 0137
-
-
-
-
-
Grenoble, France, 38043 Cedex 09
- Not yet recruiting
- Local Institution - 0047
-
Contact:
- Site 0047
-
Marseille, France, 13915
- Recruiting
- Assistance Publique Hôpitaux de Marseille - Hôpital Nord
-
Contact:
- Laurent Greillier, Site 0110
- Phone Number: 33491324400
-
Paris, France, 75014
- Recruiting
- Hopitaux Universitaires Paris Centre-Hopital Cochin
-
Contact:
- Marie Wislez, Site 0109
- Phone Number: 33158413091
-
Saint-Herblain, France, 44800
- Not yet recruiting
- Local Institution - 0085
-
Contact:
- Site 0085
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, France, 6100
- Not yet recruiting
- Local Institution - 0131
-
Contact:
- Site 0131
-
-
Hérault
-
Montpellier, Hérault, France, 34090
- Recruiting
- Hôpital Arnaud de Villeneuve - CHU Montpellier
-
Contact:
- Benoit Roch, Site 0117
- Phone Number: +33467330759
-
-
Languedoc-Roussillon
-
Montpellier, Languedoc-Roussillon, France, 34070
- Not yet recruiting
- Local Institution - 0087
-
Contact:
- Site 0087
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, France, 94800
- Not yet recruiting
- Local Institution - 0119
-
Contact:
- Site 0119
-
-
Île-de-France Region
-
Paris, Île-de-France Region, France, 75005
- Not yet recruiting
- Local Institution - 0019
-
Contact:
- Site 0019
-
-
-
-
-
Cologne, Germany, 51109
- Recruiting
- Klinikum Köln-Merheim
-
Contact:
- Eva-Lotte Buchmeier, Site 0065
- Phone Number: +49221890713962
-
Halle, Germany, 06120
- Recruiting
- Christliches Klinikum Halle (Saale) GmbH
-
Contact:
- Miriam Moeller, Site 0042
- Phone Number: 00493455591440
-
Hessen, Germany, 60590
- Recruiting
- Universitatsklinikum Frankfurt
-
Contact:
- Friederike Althoff, Site 0125
-
-
Baden-Wurttemberg
-
Stuttgart, Baden-Wurttemberg, Germany, 70376
- Recruiting
- Robert Bosch Krankenhaus
-
Contact:
- Martin Kimmich, Site 0126
- Phone Number: 4971181017719
-
-
Hesse
-
Marburg, Hesse, Germany, 35043
- Not yet recruiting
- Local Institution - 0156
-
Contact:
- Site 0156
-
-
Saarland
-
Homburg, Saarland, Germany, 66424
- Not yet recruiting
- Local Institution - 0152
-
Contact:
- Site 0152
-
-
-
-
-
Bari, Italy, 70124
- Not yet recruiting
- Local Institution - 0043
-
Contact:
- Site 0043
-
Milan, Italy, 20142
- Not yet recruiting
- Local Institution - 0159
-
Contact:
- Site 0159
-
Ravenna, Italy, 48121
- Not yet recruiting
- Local Institution - 0014
-
Contact:
- Site 0014
-
Rozzano (MI), Italy, 20089
- Not yet recruiting
- Local Institution - 0011
-
Contact:
- Site 0011
-
-
BG
-
Bergamo, BG, Italy, 24127
- Not yet recruiting
- Local Institution - 0148
-
Contact:
- Site 0148
-
-
Catania
-
Misterbianco, Catania, Italy, 95045
- Recruiting
- Humanitas Istituto Clinico Catanese
-
Contact:
- Alessandro Russo, Site 0128
- Phone Number: 393280569761
-
-
-
-
-
Bucharest, Romania, 022328
- Recruiting
- Institutul Oncologic "Prof. Dr. Alexandru Trestioreanu" Bucuresti (IOB)
-
Contact:
- Aurelia Alexandru, Site 0076
- Phone Number: 40723289606
-
Cluj-Napoca, Romania, 400015
- Recruiting
- Institutul Oncologic Cluj
-
Contact:
- Tudor Ciuleanu, Site 0008
- Phone Number: 40745646368
-
Craiova, Romania, 200347
- Recruiting
- Centrul de Oncologie Sf. Nectarie SRL
-
Contact:
- Michael Schenker, Site 0075
- Phone Number: 40727774974
-
Iași, Romania, 700483
- Recruiting
- Institutul Regional de Oncologie Iasi
-
Contact:
- Dana Clement, Site 0116
- Phone Number: 40744692062
-
Iași, Romania, 700106
- Recruiting
- Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center)
-
Contact:
- Constantin Volovat, Site 0115
- Phone Number: 40746110096
-
Timisoara, Timis, Romania, 300239
- Recruiting
- Oncohelp
-
Contact:
- Daniela Sirbu, Site 0113
- Phone Number: 40744571617
-
-
Cluj
-
Florești, Cluj, Romania, 407280
- Recruiting
- Amethyst Radiotherapy Center-Oncologie Medicala
-
Contact:
- Andrei Ungureanu, Site 0114
- Phone Number: 40742206212
-
-
-
-
-
Barcelona, Spain, 8036
- Not yet recruiting
- Local Institution - 0163
-
Contact:
- Site 0163
-
Barcelona, Spain, 08041
- Recruiting
- Hospital de la Santa Creu i Sant Pau
-
Contact:
- Margarita Majem Tarruella, Site 0068
- Phone Number: 34935565651
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitari Vall D'Hebron
-
Contact:
- Enriqueta Felip Font, Site 0027
- Phone Number: 34932746077
-
Madrid, Spain, 28041
- Withdrawn
- Local Institution - 0041
-
Majadahonda, Spain, 28222
- Not yet recruiting
- Local Institution - 0010
-
Contact:
- Site 0010
-
Málaga, Spain, 29010
- Recruiting
- Hospital Carlos Haya De Malaga
-
Contact:
- Manuel Cobo-Dols, Site 0020
- Phone Number: 00349422033350000
-
-
Barcelona
-
Badalona, Barcelona, Spain, 8916
- Not yet recruiting
- Local Institution - 0132
-
Contact:
- Site 0132
-
-
Seville
-
Seville, Seville, Spain, 41013
- Not yet recruiting
- Local Institution - 0162
-
Contact:
- Site 0162
-
-
-
-
-
Guildford, United Kingdom, GU2 7XX
- Recruiting
- The Royal Surrey County Hospital NHS Foundation Trust
-
Contact:
- Ali Suwaidan, Site 0037
- Phone Number: 01483571122
-
-
BIR
-
Birmingham, BIR, United Kingdom, B9 5SS
- Not yet recruiting
- Local Institution - 0182
-
Contact:
- Site 0182
-
-
Greater London
-
London, Greater London, United Kingdom, SE19RT
- Not yet recruiting
- Local Institution - 0035
-
Contact:
- Site 0035
-
-
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20016
- Not yet recruiting
- Local Institution - 0183
-
Contact:
- Site 0183
-
-
Georgia
-
Athens, Georgia, United States, 30607
- Recruiting
- University Cancer & Blood Center, LLC
-
Contact:
- Frederick Flynt Jr, Site 0170
- Phone Number: 402-334-4773
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Recruiting
- Baptist Health Lexington
-
Contact:
- Firas Badin, Site 0034
- Phone Number: 859-276-0414
-
Lexington, Kentucky, United States, 40509
- Recruiting
- Baptist Health Hamburg
-
Contact:
- Firas Badin, Site 0171
- Phone Number: 859-260-6100
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Not yet recruiting
- Local Institution - 0123
-
Contact:
- Site 0123
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Recruiting
- Hattiesburg Clinic
-
Contact:
- John Hrom, Site 0180
- Phone Number: 601-261-1700
-
-
Nebraska
-
Grand Island, Nebraska, United States, 68803
- Recruiting
- Nebraska Cancer Specialists
-
Contact:
- Joel Michalski, Site 0172
- Phone Number: 402-955-2691
-
Omaha, Nebraska, United States, 68130
- Recruiting
- Oncology Hematology West PC
-
Contact:
- Joel Michalski, Site 0102
- Phone Number: 402-955-2691
-
-
New York
-
New York, New York, United States, 10021
- Not yet recruiting
- Local Institution - 0080
-
Contact:
- Site 0080
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Not yet recruiting
- Local Institution - 0176
-
Contact:
- Site 0176
-
-
Texas
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Local Institution - 0095
-
Contact:
- Site 0095
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Not yet recruiting
- Local Institution - 0135
-
Contact:
- Site 0135
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.
- Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
- Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site.
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Exclusion Criteria
- Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.
- Participants must not have prior treatment with immuno-oncology therapies.
- Participants must not have untreated central nervous system (CNS) metastases.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm A: Pumitamig + Imzokitug + Histology-based PDCT
|
Specified dose on specified days Specified dose on specified days Specified dose on specified days Specified dose on specified days
Other Names:
Specified dose on specified days Specified dose on specified days
Other Names:
|
|
Experimental: Arm B: Pumitamig + Imzokitug + Histology-based PDCT
|
Specified dose on specified days Specified dose on specified days Specified dose on specified days Specified dose on specified days
Other Names:
Specified dose on specified days Specified dose on specified days
Other Names:
|
|
Experimental: Arm C: Pumitamig + Imzokitug + Histology-based PDCT
|
Specified dose on specified days Specified dose on specified days Specified dose on specified days Specified dose on specified days
Other Names:
Specified dose on specified days Specified dose on specified days
Other Names:
|
|
Experimental: Arm D: Pumitamig + Histology-based PDCT
|
Specified dose on specified days Specified dose on specified days Specified dose on specified days Specified dose on specified days
Other Names:
Specified dose on specified days |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival (OS)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
|
Number of participants with adverse events (AEs)
Time Frame: Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of participants with serious adverse events (SAEs)
Time Frame: Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of participants with treatment-related AEs
Time Frame: Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of participants with treatment-related SAEs
Time Frame: Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of participants with AEs leading to discontinuation
Time Frame: Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of deaths
Time Frame: Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Progression free survival (PFS) by investigator (per RECIST v1.1)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
|
Duration of response (DOR) by investigator (per RECIST v1.1)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
|
Time to recurrence (TTR) by investigator (per RECIST v1.1)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Amino Acids, Peptides, and Proteins
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Inorganic Chemicals
- Chlorine Compounds
- Nitrogen Compounds
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Taxoids
- Cyclodecanes
- Diterpenes
- Platinum Compounds
- Pemetrexed
- Carboplatin
- Paclitaxel
- Cisplatin
Other Study ID Numbers
- CA052-1000
- 2026-525170-19 (Other Identifier: EU CT Number)
- U1111-1333-5867 (Other Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD Sharing Time Frame
See Plan Description
IPD Sharing Access Criteria
See Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.